GLPwatch
Papers (9189)
Page 145 of 154, ranked by citation count.
- Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care.
- Byetta update: what we've learned from experience.
- Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.
- Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.
- Liraglutide for Adolescents with Obesity.
- Novo sets sights on obesity market with diabetes drug.
- Anti-obesity compounds, Semaglutide and LiPR, and PrRP do not change the proportion of human and mouse POMC+ neurons.
- Semaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?
- Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Preliminary evaluation of 18F‑AlF‑NOTA‑MAL‑Cys40‑Exendin‑4 in rodent heart after myocardial ischemia and reperfusion.
- Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.
- Semaglutide in people with HIV-associated lipohypertrophy.
- Obesity Week 2016 Annual Meeting.
- A GLP-1 receptor agonist semaglutide attenuates cardiac microvascular injury in HFD/STZ-induced diabetic mice.
- Comment on Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double‑Blind Single‑Centre Study.
- GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
- Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity".
- Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
- South African Hypertension Society 2012 congress report.
- Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study.
- Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes.
- Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.
- GLP-1 receptor agonists and their role in managing type 2 diabetes.
- [The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters].
- Real-world effects of incretin-based Obesity medications on body composition.
- Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity.
- Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide.
- Paradigm Shifts to Improve Treatment in Youth with Type 2 Diabetes.
- Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.
- Comparative Effectiveness of Liraglutide and Dulaglutide in Heart Failure with Preserved Ejection Fraction: A Propensity Score-Matched Real-World Study.
- Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
- [Nephroprotection in patients with diabetes mellitus].
- Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction.
- Pattern of semaglutide prescription in a real-world Canadian patient cohort.
- Integrating micro-needle jet injection and sustained GLP-1 therapy with structured feeding: a comprehensive strategy for obesity management.
- Postprandiale Hyperglykämien: Rascheres Insulin aspart, einmal wöchentliches Semaglutid.
- Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
- Effect of semaglutide on major cardiovascular events.
- Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction.
- Drug used to treat diabetes may get ok for weight loss.
- Fathoming the Role of Semaglutide in Obesity Therapeutics.
- [In Process Citation].
- Higher Compliance with Treatment Administration Instructions for Injectable Dulaglutide versus Oral Semaglutide Reported by People with Type 2 Diabetes in Clinical Practice Settings in Spain: The TRU-Experience Study.
- Olive-derived elenolic acid surpasses metformin and rivals liraglutide in managing blood glucose and obesity in a mouse model of type 2 diabetes.
- Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
- [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
- [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
- Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
- [New drugs in type 2 diabetes mellitus therapy].
- Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis.
- Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
- Meeting of the minds: Send your stories.
- Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis.
- In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved histologic steatohepatitis and fibrosis at 72 wk.
- The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
- Weight management treatment in obesity.
- [Effects of glucagon-like peptide 1 and its receptor agonist - liraglutide on cardiovascular system].
- Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching.
- Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.